Literature DB >> 10674623

Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein.

J Fergusson1, M Landon, J Lowe, L Ward, F W van Leeuwen, R J Mayer.   

Abstract

In Alzheimer's disease (AD) neurofibrillary tangles (NFT) are strongly tau and ubiquitin immunopositive, and contain an aberrant form of ubiquitin derived from the ubiquitin-B gene denoted as UBB+1. We explored whether the tau-related NFT seen in another neurodegenerative disease, progressive supranuclear palsy (PSP), also showed an accumulation of UBB+1. Three cases of PSP were examined immunohistochemically for tau protein, ubiquitin-protein conjugates and UBB+1 using single and double labelling. We conclude that UBB+1 is associated with compact globose tangles rather than dispersed accumulations of tau in PSP, showing that its presence is not unique to AD. We propose that aggregation of ubiquitinated proteins into compact inclusions in PSP might be due to inhibition of the degradation of multiubiquitinated proteins by ubiquitin chains containing proximal UBB+1 rather than normal ubiquitin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674623     DOI: 10.1016/s0304-3940(99)00917-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 2.  Progressive supranuclear palsy.

Authors:  K Tawana; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

3.  Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis.

Authors:  J A Johnston; M J Dalton; M E Gurney; R R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

4.  Inhibition of the ubiquitin-proteasome system in Alzheimer's disease.

Authors:  Y A Lam; C M Pickart; A Alban; M Landon; C Jamieson; R Ramage; R J Mayer; R Layfield
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 5.  Linkage between the proteasome pathway and neurodegenerative diseases and aging.

Authors:  Sophie Vigouroux; Marièle Briand; Yves Briand
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

6.  Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation.

Authors:  Kristina Lindsten; Femke M S de Vrij; Lisette G G C Verhoef; David F Fischer; Fred W van Leeuwen; Elly M Hol; Maria G Masucci; Nico P Dantuma
Journal:  J Cell Biol       Date:  2002-04-29       Impact factor: 10.539

Review 7.  A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy.

Authors:  Kundlik Gadhave; Deepak Kumar; Vladimir N Uversky; Rajanish Giri
Journal:  Med Res Rev       Date:  2020-08-11       Impact factor: 12.388

8.  Top-down proteomics with mass spectrometry imaging: a pilot study towards discovery of biomarkers for neurodevelopmental disorders.

Authors:  Hui Ye; Rakesh Mandal; Adam Catherman; Paul M Thomas; Neil L Kelleher; Chrysanthy Ikonomidou; Lingjun Li
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 9.  The Dose-Dependent Pleiotropic Effects of the UBB+1 Ubiquitin Mutant.

Authors:  Katarzyna Banasiak; Natalia A Szulc; Wojciech Pokrzywa
Journal:  Front Mol Biosci       Date:  2021-03-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.